Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (211-220 of 289) with videos related to

Pageof 29
Sort By:
Scientific Reports|November 26, 2015
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachoneGaurab Chakrabarti, Molly A Silvers, Mariya Ilcheva, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Clinical Lung Cancer|January 22, 2021
Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical SystemDavid E Gerber, Heidi A Hamann, Olivia Dorsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancerPuneeth Iyengar, Brian D Kavanagh, Zabi Wardak, et al.
Cancer Immunology, Immunotherapy : CII|May 14, 2026
Correction: Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Population Health Management|May 23, 2023
Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation InterventionSimon J Craddock Lee, Jessica Lee, Hong Zhu, et al.
Journal for Immunotherapy of Cancer|January 6, 2025
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer modelsRyan R Kowash, Manoj Sabnani, Laura T Gray, et al.
The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Eclinicalmedicine|October 7, 2025
Osimertinib plus consolidative radiotherapy for advanced <i>EGFR</i> mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trialSagus Sampath, Sawsan Rashdan, Puneeth Iyengar, et al.
Pageof 29

Showing results (211-220 of 289) with videos related to

Sort By:
Pageof 29
Scientific Reports|November 26, 2015
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachoneGaurab Chakrabarti, Molly A Silvers, Mariya Ilcheva, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Clinical Lung Cancer|January 22, 2021
Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical SystemDavid E Gerber, Heidi A Hamann, Olivia Dorsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancerPuneeth Iyengar, Brian D Kavanagh, Zabi Wardak, et al.
Cancer Immunology, Immunotherapy : CII|May 14, 2026
Correction: Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Population Health Management|May 23, 2023
Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation InterventionSimon J Craddock Lee, Jessica Lee, Hong Zhu, et al.
Journal for Immunotherapy of Cancer|January 6, 2025
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer modelsRyan R Kowash, Manoj Sabnani, Laura T Gray, et al.
The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Eclinicalmedicine|October 7, 2025
Osimertinib plus consolidative radiotherapy for advanced <i>EGFR</i> mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trialSagus Sampath, Sawsan Rashdan, Puneeth Iyengar, et al.
Pageof 29